Galderma
Galderma, a leading global dermatology company, is headquartered in the United States and operates extensively across Europe, Asia, and Latin America. Founded in 1981, Galderma has established itself as a pioneer in the field of medical and aesthetic dermatology, focusing on innovative solutions for skin health. The company is renowned for its core products, including the Restylane® range of dermal fillers and the Sculptra® aesthetic treatment, which are distinguished by their unique formulations and proven efficacy. Galderma's commitment to research and development has positioned it as a trusted name in the industry, with a strong market presence and notable achievements in advancing dermatological care. With a focus on enhancing skin health and beauty, Galderma continues to lead the way in dermatological innovation.
DitchCarbon Score
How does Galderma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Galderma's score of 6 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Galderma's reported carbon emissions
In 2023, Galderma reported total carbon emissions of approximately 340,200 kg CO2e, comprising 7,600 kg CO2e from Scope 1, 5,500 kg CO2e from Scope 2, and a significant 332,100 kg CO2e from Scope 3 emissions. The company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. This lack of formal commitments highlights an opportunity for Galderma to enhance its climate strategy and align with industry standards for sustainability. As a global leader in dermatology, Galderma's emissions profile underscores the importance of addressing carbon footprints across all scopes, particularly in Scope 3, which often represents the largest share of total emissions for companies in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2023 | |
|---|---|
| Scope 1 | 7,600 |
| Scope 2 | 5,500 |
| Scope 3 | 332,100 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Galderma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
